Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Samsung will manufacture commercial drug substances and drug product at Incheon manufacturing site.

Bristol-Myers Squibb Company and Samsung BioLogics have announced that the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

"Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline,” said Lou Schmukler, president, Global Manufacturing & Supply. “The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients.”

"Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production," said Dr. TH Kim, president and CEO of Samsung BioLogics. “It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship.”

Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location.

In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
ViiV will pay upfront payments totaling $350 million to Bristol-Myers Squibb.
Tuesday, December 29, 2015
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics
Strategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients.
Saturday, October 24, 2015
BMS and Moffitt Cancer Center Enter Into a Collaboration Agreement
Agreement as part of U.S. Immuno-Oncology Rare Population Malignancy program.
Saturday, October 03, 2015
Bristol-Myers Squibb and Promedior Enters into Agreement
Agreement providing exclusive right to acquire Promedior, Inc. and its novel PRM-151 in development for fibrotic diseases.
Thursday, September 03, 2015
Bristol-Myers Squibb and uniQure Enter into Strategic Collaboration
Collaboration to develop gene therapies for cardiovascular diseases.
Thursday, April 09, 2015
Bristol-Myers Squibb to Expand its Immuno-Oncology Pipeline
Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program.
Thursday, February 26, 2015
Bristol-Myers Squibb and Calibr Collaborate
Collaboration and license agreement focused on new treatment approaches for fibrotic diseases.
Thursday, January 08, 2015
BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Ireland
Facility will produce multiple therapies for the company’s growing biologics portfolio.
Tuesday, November 25, 2014
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza’s Portsmouth facility.
Friday, November 07, 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration
Collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma.
Thursday, October 16, 2014
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers.
Thursday, August 21, 2014
B-MS, Syngene Extend Research Collaboration
Companies announce a five-year extension of their drug discovery and development collaboration in India.
Wednesday, June 04, 2014
Bristol-Myers Squibb Acquires iPierian
B-MS acquires iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, for $175M.
Thursday, May 01, 2014
U.S. FDA Approves DVT Drug Eliquis®
The approval gives U.S. orthopedic surgeons a new option for DVT prophylaxis in both hip and knee replacement surgery.
Monday, March 17, 2014
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
Treatment effects of Eliquis® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE.
Tuesday, May 07, 2013
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!